TY - JOUR
T1 - Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
AU - EMPEROR-Preserved Trial Committees and Investigators
AU - Anker, Stefan D.
AU - Butler, Javed
AU - Filippatos, Gerasimos
AU - Shahzeb Khan, Muhammad
AU - Ferreira, João Pedro
AU - Bocchi, Edimar
AU - Böhm, Michael
AU - Brunner-La Rocca, Hans Pieter
AU - Choi, Dong Ju
AU - Chopra, Vijay
AU - Chuquiure, Eduardo
AU - Giannetti, Nadia
AU - Gomez-Mesa, Juan Esteban
AU - Janssens, Stefan
AU - Januzzi, James L.
AU - Gonzalez-Juanatey, Jose R.
AU - Merkely, Bela
AU - Nicholls, Stephen J.
AU - Perrone, Sergio V.
AU - Piña, Ileana L.
AU - Ponikowski, Piotr
AU - Senni, Michele
AU - Seronde, Marie France
AU - Sim, David
AU - Spinar, Jindrich
AU - Squire, Iain
AU - Taddei, Stefano
AU - Tsutsui, Hiroyuki
AU - Verma, Subodh
AU - Vinereanu, Dragos
AU - Zhang, Jian
AU - Jamal, Waheed
AU - Schnaidt, Sven
AU - Schnee, Janet M.
AU - Brueckmann, Martina
AU - Pocock, Stuart J.
AU - Zannad, Faiez
AU - Packer, Milton
N1 - Funding Information:
The EMPEROR‐Preserved trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.
Publisher Copyright:
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2020/12
Y1 - 2020/12
N2 - Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
AB - Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
UR - http://www.scopus.com/inward/record.url?scp=85100342570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100342570&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2064
DO - 10.1002/ejhf.2064
M3 - Article
C2 - 33251670
AN - SCOPUS:85100342570
SN - 1388-9842
VL - 22
SP - 2383
EP - 2392
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 12
ER -
